Right now, several vaccines are already rolling out in the market, although the supply is still very limited. For instance, in the United States, several vaccines are still up for approval from the Food and Drug Administration (FDA).
To ensure safety, each of the coronavirus vaccine brands must have passed through the three phases of tests. Phase 3 of the tests require the participation of tens of thousands of people for the clinical and medical observation of the vaccine.
For the time being, the United States has already approved the use of two coronavirus (COVID-19) vaccines:
A. the Pfizer-BioNTech COVID-19 vaccine
B. the Moderna COVID-19 vaccine
On another note, the Pfizer-BioNTech vaccine, developed in Germany, became ready for rollout last December 11, 2020, after receiving FDA approval.
During the Pfizer-BioNTech COVID-19 vaccine trial, 43,000 people took part in phase 3 of its trial. To note, around half received a placebo, and the half received 2 doses, 21 days apart. The results showed 95% efficiency at protecting against COVID-19.
On the other hand, the Moderna vaccine, developed in Cambridge, MA, also received approval for emergency use in the U.S. on December 18. In a phase 3 trial, 30,000 volunteers received the vaccine from either a placebo or two doses of the vaccine, 28 days apart. The results showed 94% efficiency.
Other vaccines approved in other countries:
-The Oxford AstraZeneca vaccine, in the United Kingdom
-Coronavac, developed by Sinovac, in China
–The Sputnik V vaccine, in Russia
-Covaxin, developed by Bharat Biotech, in India
Meanwhile, the Novavax vaccine is currently undergoing phase 3 trials, as is Janssen’s COVID-19 vaccine. Companies based in the U.S. developed both these vaccines. For the latest update on vaccine developments, you may check the updates on the Regulatory Affairs Professionals Society’s COVID-19 vaccine tracker.